In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DS Biopharma

www.dsbiopharma.com

Latest From DS Biopharma

Appointments: EFPIA, Celgene, AcelRx, PureTech Health, Symbiomix, CRISPR Therapeutics and Achaogen

This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.

Appointments

Pipeline Watch: Phase III Trials In Prostate Cancer, Diffuse Large B-cell Lymphoma

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Research & Development Pipeline Watch

Deals Shaping the Medical Industry, September 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.

Deals BioPharmaceutical

The NASH Pipeline: Replete With Targets And New Compounds

The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.

Liver & Hepatic Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Inflammation
  • Alias(es)
  • Dignity Sciences Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • DS Biopharma
  • Senior Management
  • John Climax, PhD, CEO
    Mark O'Neill, CFO
    Mehar S Manku, PhD, CSO
  • Contact Info
  • DS Biopharma
    Phone: 12933590
    Trintech Bldg. South
    County Bus. Pk.
    Leopardstown, 18
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register